Radioresistant tumours: From identification to targeting. 2020

É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
Department of radiation oncology, institut Claudius-Regaud, IUCT-O, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France; Inserm UMR 1037, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France; Centre de recherches en cancérologie de Toulouse, 1, avenue Irène-Joliot-Curie, 31059 Toulouse cedex 9, France.

From surviving fraction to tumour curability, definitions of tumour radioresistance may vary depending on the view angle. Yet, mechanisms of radioresistance have been identified and involve tumour-specific oncogenic signalling pathways, tumour metabolism and proliferation, tumour microenvironment/hypoxia, genomics. Correlations between tumour biology (histology) and imaging allow theragnostic approaches that use non-invasive biological imaging using tracer functionalization of tumour pathway biomarkers, imaging of hypoxia, etc. Modelling dose prescription function based on their tumour radio-resistant factor enhancement ratio, related to metabolism, proliferation, hypoxia is an area of investigation. Yet, the delivery of dose painting by numbers/voxel-based radiotherapy with low lineal energy transfer particles may be limited by the degree of modulation complexity needed to achieve the doses needed to counteract radioresistance. Higher lineal energy transfer particles or combinations of different particles, or combinations with drugs and devices such as done with radioenhancing nanoparticles may be promising.

UI MeSH Term Description Entries
D011836 Radiation Tolerance The ability of some cells or tissues to survive lethal doses of IONIZING RADIATION. Tolerance depends on the species, cell type, and physical and chemical variables, including RADIATION-PROTECTIVE AGENTS and RADIATION-SENSITIZING AGENTS. Radiation Sensitivity,Radiosensitivity,Sensitivity, Radiation,Tolerance, Radiation,Radiation Sensitivities,Radiation Tolerances,Radiosensitivities,Sensitivities, Radiation,Tolerances, Radiation
D001932 Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. Brain Cancer,Brain Metastases,Brain Tumors,Cancer of Brain,Malignant Primary Brain Tumors,Neoplasms, Intracranial,Benign Neoplasms, Brain,Brain Neoplasm, Primary,Brain Neoplasms, Benign,Brain Neoplasms, Malignant,Brain Neoplasms, Malignant, Primary,Brain Neoplasms, Primary Malignant,Brain Tumor, Primary,Brain Tumor, Recurrent,Cancer of the Brain,Intracranial Neoplasms,Malignant Neoplasms, Brain,Malignant Primary Brain Neoplasms,Neoplasms, Brain,Neoplasms, Brain, Benign,Neoplasms, Brain, Malignant,Neoplasms, Brain, Primary,Primary Brain Neoplasms,Primary Malignant Brain Neoplasms,Primary Malignant Brain Tumors,Benign Brain Neoplasm,Benign Brain Neoplasms,Benign Neoplasm, Brain,Brain Benign Neoplasm,Brain Benign Neoplasms,Brain Cancers,Brain Malignant Neoplasm,Brain Malignant Neoplasms,Brain Metastase,Brain Neoplasm,Brain Neoplasm, Benign,Brain Neoplasm, Malignant,Brain Neoplasms, Primary,Brain Tumor,Brain Tumors, Recurrent,Cancer, Brain,Intracranial Neoplasm,Malignant Brain Neoplasm,Malignant Brain Neoplasms,Malignant Neoplasm, Brain,Neoplasm, Brain,Neoplasm, Intracranial,Primary Brain Neoplasm,Primary Brain Tumor,Primary Brain Tumors,Recurrent Brain Tumor,Recurrent Brain Tumors,Tumor, Brain
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D050397 Radiotherapy, Intensity-Modulated CONFORMAL RADIOTHERAPY that combines several intensity-modulated beams to provide improved dose homogeneity and highly conformal dose distributions. Helical Tomotherapy,Intensity-Modulated Arc Therapy,Volumetric-Modulated Arc Therapy,Arc Therapies, Intensity-Modulated,Arc Therapies, Volumetric-Modulated,Arc Therapy, Intensity-Modulated,Arc Therapy, Volumetric-Modulated,Helical Tomotherapies,Intensity Modulated Arc Therapy,Intensity-Modulated Arc Therapies,Intensity-Modulated Radiotherapies,Intensity-Modulated Radiotherapy,Radiotherapies, Intensity-Modulated,Radiotherapy, Intensity Modulated,Therapies, Intensity-Modulated Arc,Therapies, Volumetric-Modulated Arc,Therapy, Intensity-Modulated Arc,Therapy, Volumetric-Modulated Arc,Tomotherapies, Helical,Tomotherapy, Helical,Volumetric Modulated Arc Therapy,Volumetric-Modulated Arc Therapies

Related Publications

É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
October 1975, The British journal of radiology,
É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
December 1974, The British journal of radiology,
É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
April 2012, Journal of cellular biochemistry,
É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
January 1994, International journal of radiation biology,
É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
January 1989, Current opinion in immunology,
É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
May 2021, Cancer letters,
É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
August 2017, Basic & clinical pharmacology & toxicology,
É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
January 2000, Drug discovery today,
É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
June 1994, Lancet (London, England),
É Cohen-Jonathan-Moyal, and V Vendrely, and L Motte, and J Balosso, and J Thariat
January 2022, Molecular diagnosis & therapy,
Copied contents to your clipboard!